| Disease | Locally destructive, mono-ostotic tumoral lesion, typically presenting in the meta-epiphysis of long tubular bones with predilection for the knee region of skeletally mature patients (more than 95% of the patients is older than 25 years). Poly-ostotic lesions are exceptionally rare, counting for less than 1% of all cases. In these cases especially brown tumour of hyperparathyreoidism should be considered, which may look histologically identical. Although defined as a benign lesion, adjacent soft tissue invasion, angiovascular invasion and pulmonary metastases (1%) may occur. |
| Phenotype / cell stem origin | Primitive mesenchymal stromal cell. |
| Embryonic origin | Mesoderm. |
| Etiology | The exact origin is still unknown, but data obtained from ultrastructural analyses and cell cultures, as well as novel molecular data, suggest that the stromal cell, or mononuclear spindle cell, is neoplastic. The mononuclear rounded cells and the osteoclastic giant cells are seen as reactive. Therefore, some suggest that stromal cell tumour is a better name, because this fits more precisely the concept of the mononuclear spindled cell (stromal cell) as neoplastic. |
| Epidemiology | This tumour represents 8% of all primary and approximately 20% of benign primary bone tumours. Mostly affecting adults in the third, fourth and fifth decade of life (72%). It is very rarely seen under the age of 10 years (1,3%). There is a slight female predominance (male/female ratio: 46,6%/53,4%). |
| Clinics | Pain of several weeks to months duration and a constantly expanding mass on X-ray, primary in the epiphysis, leading to cortex destruction, pathological fracture and soft tissue invasion. Finally ulceration of the skin occurs if not threatened. A pathological fracture could occasionally be the first sign of this tumour. |
| |  |
| |
| Mixture of three cellular components composites the tumour: tumoral spindle shaped mononuclear cells, reactive rounded mononuclear cells and diffusely scattered osteoclast type giant cells. Note that mitoses are strictly limited to the first cell type. |
| |
| Pathology | A mixture of four components can be distinguished: S pindled-shaped and rounded mononuclear cells, Osteoclastic-type giant cells and small blood vessels.
The spindle-shaped mononuclear cells are regarded as neoplastic. This cell type is thought to arise from the primitive mesenchymal stromal cell. Conventional mitotic figures are restricted to mononuclear cells. If atypical forms or strong nuclear atypia is noted, a secondary sarcomatous malignancy is almost always present. Secondary changes may be present like osteoid deposits, foci of fibrosis, collections of foamy cells or cystic degeneration. Secondary aneurysmal bone cyst formation is present in 6,5% of the cases. Mostly this is restricted to younger patients (median of 14 years). In the 2013 WHO classification, grading of histopathological features of GCTB is not considered predictive for clinical behaviour including risk for recurrent or metastatic disease. Originally, giant cell tumors of bone were histological graded into 3 grades according to Jaffe (1940) or into 4 grades (Netherlands Committee on Bone Tumours). |
| Treatment | Surgical intervention is the treatment of choice and therapeutic inhibition of osteoclast formation and activity with denosumab (RANK-RANKL inhibitor) provides another modality of treatment. Mostly a curettage followed by local adjuvant cryosurgery or phenol instillation is sufficient to eradicate this lesion and to save the joint. The use of polymethylmetacrylate for filling the cavity after curettage additively decreases the percentage of recurrences. An added advantage of using cement is that recurrences are detected sooner. Sometimes 'en bloc' resection is needed to be curative. Pulmonal metastases are treated by local excision. |
| Evolution | Non-treatment always leads to destruction of cortical bone, to soft tissue invasion and finally to ulceration of the skin. Local recurrences can occur following proper treatment, mostly indicating less radical initial resection. |
| Prognosis | Good, despite of recurrences and pulmonary metastases. In general much is depending on the surgical technique and expertise in combination with the histological grade of this tumour. Although pulmonary metastases may occur in rare cases, angiovascular invasion does not have any significant influence on its prognosis. The mortality rate due to giant cell tumour is about 4%. |
| H3F3A (Histone 3 |
| Amary F, Berisha F, Ye H, Gupta M, Gutteridge A, Baumhoer D, Gibbons R, Tirabosco R, O'Donnell P, Flanagan AM |
| 3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone Am J Surg Pathol |
| PMID 28505000 |
| |
| Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone |
| Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, Amary MF, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM |
| Nat Genet 2013 Dec;45(12):1479-82 |
| PMID 24162739 |
| |
| Giant cell tumor of bone |
| Bridge JA, Neff JR, Mouron BJ |
| Chromosomal analysis of 48 specimens and review of the literature Cancer Genet Cytogenet |
| PMID 1728946 |
| |
| Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma |
| Cleven AH, Höcker S, Briaire-de Bruijn I, Szuhai K, Cleton-Jansen AM, Bovée JV |
| Am J Surg Pathol 2015 Nov;39(11):1576-83 |
| PMID 26457357 |
| |
| Giant cell tumor of bone: a clinicopathologic study of prognostic factors |
| Masui F, Ushigome S, Fujii K |
| Pathol Int 1998 Sep;48(9):723-9 |
| PMID 9778111 |
| |
| Chromosomal anomalies exclusive of telomeric associations in giant cell tumor of bone |
| McComb EN, Johansson SL, Neff JR, Nelson M, Bridge JA |
| Cancer Genet Cytogenet 1996 Jun;88(2):163-6 |
| PMID 8640728 |
| |
| Cytogenetics of fine needle aspiration biopsies of sarcomas |
| Molenaar WM, van den Berg E, Dolfin AC, Zorgdrager H, Hoekstra HJ |
| Cancer Genet Cytogenet 1995 Oct 1;84(1):27-31 |
| PMID 7497439 |
| |
| Radiologic Atlas of Bone Tumors. |
| Mulder JD, Kroon HM, Schü HE, Taconis WK |
| Amsterdam. : page El. |
| |
| Giant Cell-Containing Tumors of Bone |
| Orosz Z, Athanasou NA |
| Surg Pathol Clin 2017 Sep;10(3):553-573 |
| PMID 28797502 |
| |
| Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics |
| Presneau N, Baumhoer D, Behjati S, Pillay N, Tarpey P, Campbell PJ, Jundt G, Hamoudi R, Wedge DC, Loo PV, Hassan AB, Khatri B, Ye H, Tirabosco R, Amary MF, Flanagan AM |
| J Pathol Clin Res 2015 Mar 16;1(2):113-23 |
| PMID 27499898 |
| |
| Clonality studies in giant cell tumor of bone |
| Schwartz HS, Eskew JD, Butler MG |
| J Orthop Res 2002 Mar;20(2):387-90 |
| PMID 11918322 |
| |
| Cytogenetic-morphologic correlations in aneurysmal bone cyst, giant cell tumor of bone and combined lesions |
| Sciot R, Dorfman H, Brys P, Dal Cin P, De Wever I, Fletcher CD, Jonson K, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Samson I, Tallini G, Van den Berghe H, Vanni R, Willén H |
| A report from the CHAMP study group Mod Pathol |
| PMID 11106078 |
| |
| Giant-cell tumour of bone metastasising to the lungs |
| Siebenrock KA, Unni KK, Rock MG |
| A long-term follow-up J Bone Joint Surg Br |
| PMID 9460951 |
| |
| Cytogenetic study of 249 consecutive patients examined for a bone tumor |
| Tarkkanen M, Kaipainen A, Karaharju E, Böhling T, Szymanska J, Heliö H, Kivioja A, Elomaa I, Knuutila S |
| Cancer Genet Cytogenet 1993 Jul 1;68(1):1-21 |
| PMID 8330278 |
| |
| Telomeric fusion is a major cytogenetic aberration of giant cell tumors of bone |
| Zheng MH, Siu P, Papadimitriou JM, Wood DJ, Murch AR |
| Pathology 1999 Nov;31(4):373-8 |
| PMID 10643009 |
| |
